Show simple item record

FieldValueLanguage
dc.contributor.authorLysaght, T
dc.contributor.authorLipworth, W
dc.contributor.authorHendl, T
dc.contributor.authorKerridge, I
dc.contributor.authorMunsie, M
dc.contributor.authorWaldby, C
dc.contributor.authorStewart, C
dc.date.accessioned2017-03-31
dc.date.available2017-03-31
dc.date.issued2017-03-29
dc.identifier.citationLysaght, T., Lipworth, W., Hendl, T., Kerridge I., Munsie, M., Waldby, C.,Stewart, C., The Deadly Business of an Unregulated Global Stem Cell Industry, Journal of Medical Ethics, Published online 29 March 2017. doi: 10.1136/medethics-2016-104046en
dc.identifier.urihttp://hdl.handle.net/2123/16573
dc.description.abstractIn 2016, the Office of the State Coroner of New South Wales released its report into the death of an Australian woman, Sheila Drysdale, who had died from complications of an autologous stem cell procedure at a Sydney clinic. In this report, we argue that Mrs Drysdale's death was avoidable, and it was the result of a pernicious global problem of an industry exploiting regulatory systems to sell unproven and unjustified interventions with stem cells.en
dc.description.sponsorshipResearch for this paper was supported with the funding from an Australian Research Council Linkage Project Grant (LP150100739) and the National University of Singapore, Office of the Deputy President (Research and Technology)—Humanities and Social Sciences Research Fund (WBS: R-171-000-055-646).en
dc.language.isoenen
dc.publisherBMJ Publishing Groupen
dc.rightsOther
dc.subjectautologous stem cellen
dc.subjectstem cell regulationen
dc.subjectstem cell interventionsen
dc.subjectautologous stem cell proceduresen
dc.titleThe Deadly Business of an Unregulated Global Stem Cell Industryen
dc.typeArticleen
dc.type.pubtypeAuthor accepted manuscripten
usyd.facultyFaculty of Medicine and Health, Sydney Health Ethics


Show simple item record

Associated file/s

Associated collections

Show simple item record

There are no previous versions of the item available.